GlassScriptPhysician profile
John R Phoenix
NPI 1013289024
$107,477.64
in general payments reported to CMS, 2019-2025
23 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44K · 2022: $42K · 2023: $19K · 2024: $1,486 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,818 · Travel and Lodging: $2,976 · Consulting Fee: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,750.00 |
| Food and Beverage | $4,818.11 |
| Travel and Lodging | $2,976.05 |
| Consulting Fee | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $53,372.22 | 2021-2025 | Epclusa, Descovy |
| Viiv Healthcare Company | $45,753.98 | 2021-2025 | Cabenuva, Apretude, Dovato |
| Napo Pharmaceuticals INC | $3,649.55 | 2021-2024 | Mytesi |
| Uswm, LLC | $1,670.27 | 2021 | |
| Abbvie INC. | $618.83 | 2021-2023 | |
| Emd Serono, INC. | $483.96 | 2021-2025 | Serostim, Serostim |
| Lupin INC. | $393.11 | 2021 | |
| Janssen Biotech, INC. | $370.99 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $252.54 | 2021-2023 | Egrifta, Trogarzo |
| Janssen Scientific Affairs, LLC | $213.92 | 2022-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $199.73 | 2021-2024 | Pifeltro, Delstrigo |
| Janssen Products, LP | $148.95 | 2021 | |
| Organon LLC | $60.31 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.64 | 2021-2022 | |
| Indivior INC. | $51.80 | 2025 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $40.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.42 | 2021 | |
| Eisai INC. | $22.52 | 2021 | |
| Exact Sciences Corporation | $22.07 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $16.46 | 2022 | |
| Clarus Therapeutics INC. | $13.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Phoenix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.